Trial · NCT03514420
Outcomes43
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 43
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change From Baseline in Fasting Triglycerides Levels at End of the Treatment (Week 27) | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. | percent change | MEAN |
| SECONDARY | Change From Baseline in Area Under the Curve (AUC) of Plasma Glucose as Assessed by Mixed Meal Test (MMT) at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure. | mg/dL*min | MEAN |
| SECONDARY | Change From Baseline in AUC of Serum Insulin as Assessed by MMT at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure. | milli international units per liter*min | MEAN |
| SECONDARY | Change From Baseline in AUC of Serum C-peptide as Assessed by MMT at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure. | ng/mL*min | MEAN |
| SECONDARY | Change From Baseline in AUC of Free Fatty Acid (FFA) as Assessed by MMT at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure. | mEq/L*min | MEAN |
| SECONDARY | Change From Baseline in AUC of Serum Ghrelin as Assessed by MMT at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure. | pg/mL*min | MEAN |
| SECONDARY | Change From Baseline in AUC of Incretin Hormone (Gastric Inhibitory Polypeptide [GIP]) as Assessed by MMT at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure. | pg/mL*min | MEAN |
| SECONDARY | Change From Baseline in AUC of Incretin Hormone (Glucagon-like Peptide -1 [GLP-1]) as Assessed by MMT at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure. | pmol/L*min | MEAN |
| SECONDARY | Change From Baseline in AUC of Peptide Tyrosine Tyrosine (PYY) as Assessed by MMT at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure. | pg/mL*min | MEAN |
| SECONDARY | Change From Baseline in HDL-C at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in LDL-C at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Total Cholesterol (TC) at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in VLDL-C at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. Here, Overall Number of participants analyzed signifies participants who were evaluable for this outcome measure. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Non-HDL-C at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in ApoB at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in ApoB-48 at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in Apolipoprotein B 100 (ApoB-100) at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in ApoA-1 at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in ApoC-III at End of the Treatment | Baseline and End of the Treatment (Week 27) | Safety set included all participants who were enrolled and received at least 1 dose of study drug. | mg/dL | MEAN |
| SECONDARY | Change From Baseline in ApoC-III: Chylomicron at End of the Treatment | Baseline and End of the Treatment (Week 27) | Data is not available as the collected Baseline samples were not sufficient to assess this outcome measure. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03514420/outcomes